Projects

With the help of its technology platform, Xintela is developing new treatments in the fields of stem cell therapy and targeted cancer therapy, with focus on indications with a high unmet medical need.

Pipeline

Indications
Discovery
Preclinical
Clinical
XSTEM
Osteoarthritis
Difficult-to-heal leg ulcers
ARDS
Other indications
EQSTEM
Joint disease horses

Stem cell therapy

Many tissues do not reconstitute after an injury but instead ”heal” with the help of scar tissue, which does not have the functionality of the original tissue. Regenerative medicine, which includes, amongst others, cell therapy,  seeks to recreate the original properties and functionality. Xintela is developing a stem cell therapy for the repair of damaged cartilage based on the company’s patented marker technology.

top

EQSTEM

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

XSTEM

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Cartilage damage – osteoarthritis

Cartilage damage is relatively common, even in young people, and can be caused by external factors such as sport injuries and obesity.  Cartilage has poor healing ability, which can lead to further damage and eventually to joint diseases such as osteoarthritis , where the cartilage is gradually broken down, resulting in severe pain. Osteoarthritis is commonly associated with knee and hip joints but can also affect other joints in the body. One in four people in Sweden over the age of 45 has osteoarthritis, the prevalence rises with age and it is the primary cause of pain and chronic disability after the age of 65.

Xintela is developing a stem cell-based product for the treatment of damaged cartilage. The product is aimed at patients with traumatic cartilage damage or early osteoarthritis. The possibility to treat cartilage damage with cell therapy has been evaluated clinically for many years but the current methods have difficulty in meeting the strict quality assurance demands, regarding identity and potency, made by regulatory authorities. Xintela is solving this problem through the use of its marker technology to identify and select those stem cells which can develop into cartilage producing cells.

The company uses donated mesenchymal stem cells which can be cultured in large volumes and which can be used to treat a large number of patients, thus keeping production costs low. In addition, the product is designed to be injected into the damaged joint and is, thus, a simple procedure for the patient.

Xintela is also developing a stem cell treatment for cartilage damage in horses, thus bringing a product to market early and at the same time preparing for clinical studies in man.

top

Svårläkta bensår

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Cancer therapy

In cancer therapy (which is run by the subsidiary Targinta AB), therapeutic antibodies that specifically bind to the target molecule integrin α10β1, which is expressed on certain aggressive cancer cells, including cancer cells in triple-negative breast cancer and the brain tumor glioblastoma.

Read more on Targinta's website
top

Publications

Camper, L., Hellman, U., and Lundgren-Åkerlund, E. Isolation, "Cloning, and Sequence Analysis of the Integrin Subunit α10, a β1-associated Collagen Binding Integrin Expressed on Chondrocytes." Journal of Biological Chemistry 273, 20383–20389 (1998).

Camper, L., Holmvall, K., Wängnerud, C., Aszódi, A., and Lundgren-Åkerlund, E.  "Distribution of the collagen-binding integrin α10β1 during mouse development."  Cell Tissue Res. 306, 107-116 (2001).

Bengtsson, T., Camper, L., Schneller, M., and Lundgren-Åkerlund, E.  "Characterization of the mouse integrin subunit α10 gene and comparison with its human homologue. Genomic structure, chromosomal localization and identification of splice variants." Matrix Biology 20, 565–76 (2001).

Bengtsson, T., Aszódi. A., Nicolae, C., Hunziker, E.B., Lundgren-Åkerlund, E., and Fässler, R.  "Loss of α10β1 integrin expression leads to moderate dysfunction of growth plate chondrocytes." Journal of Cell Science 118, 929–36 (2005).

Varas, L., Bryngelson Ohlsson, L., Honeth, G., Olsson, A., Bengtsson, T., Wiberg, C., Bockermann, R., Järnum, S., Richter, J., Pennigton, D., Johnstone, B., Lundgren-Åkerlund, E., and Kjellman, C. "α10 Integrin expression is up-regulated on fibroblast growth factor-2-treated mesenchymal stem cells with improved chondrogenic differentiation potential. " Stem Cells and Development 16, 965–978 (2007).

Lundgren-Åkerlund E., and Aszòdi A. "Integrin α10β1: a collagen receptor critical in skeletal development" Adv Exp Med Biol. 819:61-71. (2014)

Zeltz C, Lu N, Gullberg D. “Integrin α11β1: a major collagen receptor on fibroblastic cells" Adv Exp Med Biol. 819:73-83. (2014)

Munksgaard Thorén M., Chmielarska Masoumi K., Krona C., Huang X., Kundu S., Schmidt L., Forsberg-Nilsson K., Floyd Keep M., Englund E., Nelander S., Holmqvist B., and Lundgren-Åkerlund E. “Integrinα10,a Novel Therapeutic Target in Glioblastoma, Regulates Cell Migration,Proliferation, and Survival.” Cancers (Basel). 11, 587 (2019).

Uvebrant K., Reimer Rasmusson L., Talts JF., Alberton P., Aszodi A., and Lundgren-Åkerlund E. Integrinα10β1-selected Equine MSCs have Improved Chondrogenic Differentiation, Immunomodulatory and Cartilage Adhesion Capacity.”Ann Stem Cell Res. 2,001–009 (2019).

Delco ML., Goodale M., Talts JF.,Pownder SL., Koff MF., Miller AD., Nixon B., Bonassar LJ., Lundgren-Åkerlund E., and Fortier LA. Integrin α10β1-SelectedMesenchymal Stem Cells Mitigate the Progression of Osteoarthritis in an EquineTalar Impact Model.” Am J Sports Med. 48, 612-623 (2020).

Andersen, C., Uvebrant, K., Mori, Y. Aarsvold S., Jacobsen S., Berg LC., Lundgren Åkerlund, E., and Lindegaard C. ”Human integrin α10β1-selected mesenchymal stem cells home to cartilage defects in the rabbit knee and assume a chondrocyte-like phenotype.” Stem Cell Res Ther. 13, 206 (2022).

top